Obesity drug DA-1726 tested in humans for first time

NCT ID NCT06252220

Recruiting now Disease control Sponsor: NeuroBo Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called DA-1726 in 139 people with obesity. The main goal is to check safety and side effects. Researchers will also measure how the drug moves through the body and its effect on weight. Participants receive either the drug or a placebo, and neither they nor the doctors know who gets what.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DA-1726
What this could lead to: If successful, this could lead to a new weight-loss medication for people with obesity.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects. Results are years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Clinical Pharmacology of Miami, LLC
RECRUITING

Miami, Florida, 33172, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.